Cited by 571Cancer Genomics and DiagnosticsCancer Cells and MetastasisLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.

Precision medicine for cancer with next-generation functional diagnostics

Open access

Friedman, Adam A., Letai, Anthony, Fisher, David E., Flaherty, Keith T.·2015·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Precision medicine is about matching the right drugs to the right patients. Although this approach is technology agnostic, in cancer there is a tendency to make precision medicine synonymous with genomics. However, genome-based cancer therapeutic matching is limited by incomplete biological understanding of the relationship between phenotype and cancer genotype. This limitation can be addressed by functional testing of live patient tumour cells exposed to potential therapies. Recently, several 'next-generation' functional diagnostic technologies have been reported, including novel methods for tumour manipulation, molecularly precise assays of tumour responses and device-based in situ approaches; these address the limitations of the older generation of chemosensitivity tests. The promise of these new technologies suggests a future diagnostic strategy that integrates functional testing with next-generation sequencing and immunoprofiling to precisely match combination therapies to individual cancer patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc4015

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Network biology: understanding the cell's functional organization
Barabási, A.-L., & Oltvai, Z. N. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1272 · Cited by 7,903
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citation
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
Organoid Models and Applications in Biomedical Research
Xinaris, C., Brizi, V., & Remuzzi, G. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000433566 · Cited by 3,519
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citation
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices
Jorgensen, J. H., & Ferraro, M. J. (2009) · Clinical Infectious Diseases · doi:10.1086/647952 · Cited by 1,894
Interactome Networks and Human Disease
Vidal, M., Cusick, M. E., & Barabási, A.-L. (2011) · Cell · doi:10.1016/j.cell.2011.02.016 · Cited by 1,771
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
A Proteome-Scale Map of the Human Interactome Network
Rolland, T., Taşan, M., Charloteaux, B., Pevzner, S. J., Zhong, Q., Sahni, N., Yi, S. S., Lemmens, I. H., Fontanillo, C., Mosca, R., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.050 · Cited by 1,381
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,144
Droplet microfluidic technology for single-cell high-throughput screening
Brouzes, E., Medkova, M., Savenelli, N., Marran, D., Twardowski, M., Hutchison, J. B., Rothberg, J., Link, D., Perrimon, N., & Samuels, M. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0903542106 · Cited by 1,064
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
Baccelli, I., Schneeweiß, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., Klein, C., Saini, M., Bäuerle, T., Wallwiener, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2576 · Cited by 1,050
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Simon, R. M., Paik, S., & Hayes, D. F. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp335 · Cited by 1,040
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,011
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Collier, M. D., Desai, R. N., Zhu, H., Comaills, V., Zheng, Z., et al. (2014) · Science · doi:10.1126/science.1253533 · Cited by 927
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Allen, E. M. V., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A. N., Whittaker, S. R., Kryukov, G. V., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 921
ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells
Liu, X., Ory, V., Chapman, S., Yuan, H., Albanese, C., Kallakury, B., Timofeeva, O. A., Nealon, C., Dakic, A., Simic, V., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.10.036 · Cited by 726
Validating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Hodgkinson, C. L., Morrow, C. J., Li, Y., Metcalf, R. L., Rothwell, D. G., Trapani, F., Polański, R., Burt, D. J., Simpson, K., Morris, K. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3600 · Cited by 695
Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells
Irish, J. M., Hovland, R., Krutzik, P. O., Perez, O. D., Bruserud, Ø., Gjertsen, B. T., & Nolan, G. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.028 · Cited by 683
Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
Siolas, D., & Hannon, G. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1069 · Cited by 672
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T. T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P. G. G., Tai, Y., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 588
Self-citation
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Eirew, P. D., Steif, A., Khattra, J. S., Ha, G., Yap, D., Farahani, H., Gelmon, K. A., Chia, S., Mar, C., Wan, A., et al. (2014) · Nature · doi:10.1038/nature13952 · Cited by 585
The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis
Zhang, L., Ridgway, L. D., Wetzel, M. D., Ngo, J., Yin, W., Kumar, D., Goodman, J. C., Groves, M. D., & Marchetti, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005109 · Cited by 521
Inconsistency in large pharmacogenomic studies
Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C., Beck, A. H., Aerts, H. J. W. L., & Quackenbush, J. (2013) · Nature · doi:10.1038/nature12831 · Cited by 499
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 496
Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Piotrowska, Z., Niederst, M. J., Karlovich, C., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M. A., Fulton, L. E., Hata, A. N., Lockerman, E. L., Kalsy, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0399 · Cited by 467
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., et al. (2013) · Nature · doi:10.1038/nature12688 · Cited by 452
Self-citation
An In vivo Platform for Translational Drug Development in Pancreatic Cancer
Rubio‐Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio–Donahue, C. A., Karikari, C. A., Shi, C., Danenberg, K. D., Danenberg, P. V., Kuramochi, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0113 · Cited by 414
A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Hidalgo, M. M., Bruckheimer, E. M., Rajeshkumar, N. V., Garrido‐Laguna, I., Oliveira, E. D., Rubio‐Viqueira, B., Strawn, S. J., Wick, M. J., Martell, J., & Sidransky, D. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0233 · Cited by 406
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
(2013) · doi:10.1158/2159-8290.cd-13-0350 · Cited by 393
Organoid cultures for the analysis of cancer phenotypes
Sachs, N., & Clevers, H. C. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.012 · Cited by 381
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378
Self-citation
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
Yadav, B., Pemovska, T., Szwajda, A., Kulesskiy, E., Kontro, M., Karjalainen, R., Majumder, M. M., Malani, D., Murumägi, A., Knowles, J., et al. (2014) · Scientific Reports · doi:10.1038/srep05193 · Cited by 358
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Vo, T.-T. T., Ryan, J. A., Carrasco, R. D., Neuberg, D. S., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. G. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 356
Self-citation
Examining the utility of patient-derived xenograft mouse models
Aparicio, S. A. J. R., Hidalgo, M. M., & Kung, A. L. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3944 · Cited by 352
Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
Majumder, B., Ulaganathan, B., Thiyagarajan, S., Radhakrishnan, P., Narasimhan, H., Dhandapani, M., Brijwani, N., Pinto, D. D., Prasath, A., Shanthappa, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms7169 · Cited by 317
Implementing personalized cancer genomics in clinical trials
Simon, R. M., & Roychowdhury, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3979 · Cited by 309
In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities
Rubio-Perez, C., Tamborero, D., Schroeder, M. P., Antolín, A. A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., & Lopez-Bigas, N. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.007 · Cited by 296
Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells
Suprynowicz, F. A., Upadhyay, G., Krawczyk, E., Kramer, S. C., Hebert, J. D., Liu, X., Yuan, H., Cheluvaraju, C., Clapp, P. W., Boucher, R. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213241109 · Cited by 291
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Lee, R. J., Nolop, K. B., & Saltz, L. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3534 · Cited by 283
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors
Vaira, V., Fedele, G., Pyne, S., Fasoli, E., Zadra, G., Bailey, D., Snyder, E. L., Faversani, A., Coggi, G., Flavin, R., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907676107 · Cited by 282
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Herbst, R. S., Gandara, D. R., Hirsch, F. R., Redman, M. W., LeBlanc, M. L., Mack, P. C., Schwartz, L. H., Vokes, E. E., Ramalingam, S. S., Bradley, J. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3473 · Cited by 245
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Pemovska, T., Johnson, E., Kontro, M., Repasky, G. A., Chen, J., Wells, P., Cronin, C. N., McTigue, M., Kallioniemi, O., Porkka, K., et al. (2015) · Nature · doi:10.1038/nature14119 · Cited by 234
Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2007 · Cited by 233
Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia
Ridky, T. W., Chow, J. M., Wong, D. J., & Khavari, P. A. (2010) · Nature Medicine · doi:10.1038/nm.2265 · Cited by 217
High-content single-cell drug screening with phosphospecific flow cytometry
Krutzik, P. O., Crane, J., Clutter, M. R., & Nolan, G. P. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.59 · Cited by 208
American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays
Schrag, D., Garewal, H. S., Burstein, H. J., Samson, D. J., Hoff, D. D. V., & Somerfield, M. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.065 · Cited by 206
BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions
Moore, V. D. G., & Letai, A. G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.021 · Cited by 201
Self-citation
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Jonas, O., Landry, H. M., Fuller, J. E., Santini, J. T., Baselga, J., Tepper, R. I., Cima, M. J., & Langer, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010564 · Cited by 189
Highly Specific Prediction of Antineoplastic Drug Resistance With an In Vitro Assay Using Suprapharmacologic Drug Exposures
Kern, D. H., & Weisenthal, L. M. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.7.582 · Cited by 176
Genomic impact of transient low-dose decitabine treatment on primary AML cells
Klco, J. M., Spencer, D. H., Westover, T., Sarkaria, S. M., Wylie, T., Magrini, V. J., Hundal, J., Walker, J., Varghese, N., Erdmann-Gilmore, P., et al. (2013) · Blood · doi:10.1182/blood-2012-09-459313 · Cited by 172
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy
Kenny, H. A., Lal‐Nag, M., White, E. A., Shen, M., Chiang, C.-Y., Mitra, A. K., Zhang, Y., Curtis, M., Schryver, E. M., Bettis, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7220 · Cited by 172
Use of Reprogrammed Cells to Identify Therapy for Respiratory Papillomatosis
Yuan, H., Myers, S. A., Wang, J., Zhou, D., Woo, J. A.-L., Kallakury, B., Ju, A. W., Bazylewicz, M., Carter, Y. M., Albanese, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203055 · Cited by 167
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Wander, S. A., Levis, M. J., & Fathi, A. T. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714532123 · Cited by 166
Ibrutinib: First Global Approval
Cameron, F., & Sanford, M. (2014) · Drugs · doi:10.1007/s40265-014-0178-8 · Cited by 163
Patient‐derived xenografts for individualized care in advanced sarcoma
Stebbing, J., Paz, K., Schwartz, G. K., Wexler, L. H., Maki, R. G., Pollock, R. E., Morris, R., Cohen, R., Shankar, A., Blackman, G., et al. (2014) · Cancer · doi:10.1002/cncr.28696 · Cited by 157
Bone sarcomas as second malignant neoplasms following childhood cancer
Newton, W. A., Meadows, A. T., Shimada, H., Bunin, G. R., & Vawter, G. F. (1991) · Cancer · doi:10.1002/1097-0142(19910101)67:1 · Cited by 150
Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening
Tyner, J. W., Yang, W. F., Bankhead, A., Fan, G., Fletcher, L. B., Bryant, J. A., Glover, J., Chang, B. H., Spurgeon, S. E. F., Fleming, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1906 · Cited by 150
Database of Genomic Biomarkers for Cancer Drugs and Clinical Targetability in Solid Tumors
Dienstmann, R., Jang, I. S., Bot, B. M., Friend, S. H., & Guinney, J. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1118 · Cited by 142
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays
Burstein, H. J., Mangu, P. B., Somerfield, M. R., Schrag, D., Samson, D. J., Holt, L., Zelman, D., & Ajani, J. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0354 · Cited by 139
Chemotherapy Sensitivity and Resistance Assays: A Systematic Review
Samson, D. J., Seidenfeld, J., Ziegler, K. M., & Aronson, N. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.077 · Cited by 129
Mutational Robustness of Ribosomal Protein Genes
Lind, P. A., Berg, O. G., & Andersson, D. I. (2010) · Science · doi:10.1126/science.1194617 · Cited by 127
Idelalisib: First Global Approval
Markham, A. (2014) · Drugs · doi:10.1007/s40265-014-0285-6 · Cited by 119
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer
Cree, I. A., Kurbacher, C. M., Lamont, A., Hindley, A. C., & Love, S. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3281de727e · Cited by 102
RNAi screen for rapid therapeutic target identification in leukemia patients
Tyner, J. W., Deininger, M. W., Loriaux, M., Chang, B. H., Gotlib, J. R., Willis, S. G., Erickson, H. S., Kovacsovics, T. J., O’Hare, T., Heinrich, M. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903233106 · Cited by 99
Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
Hatzis, C., Bedard, P. L., Birkbak, N. J., Beck, A. H., Aerts, H. J. W. L., Stern, D. F., Shi, L. M., Clarke, R. C., Quackenbush, J. F., & Haibe‐Kains, B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0725 · Cited by 96
“In vitro” 3D models of tumor-immune system interaction
Hirt, C., Papadimitropoulos, A., Mele, V., Muraro, M. G., Mengus, C., Iezzi, G., Terracciano, L., Martín, I., & Spagnoli, G. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.003 · Cited by 93
A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor
Klinghoffer, R. A., Bahrami, S.-B., Hatton, B. A., Frazier, J. P., Moreno‐Gonzalez, A., Strand, A. D., Kerwin, W. S., Casalini, J. R., Thirstrup, D. J., You, S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7489 · Cited by 90
The molecular portrait of in vitro growth by meta-analysis of gene-expression profiles
Sandberg, R., & Ernberg, I. (2005) · Genome Biology · doi:10.1186/gb-2005-6-8-r65 · Cited by 84
Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer
Mengelbier, L. H., Karlsson, J., Lindgren, D., Valind, A., Lilljebjörn, H., Jansson, C., Bexell, D., Braekeveldt, N., Ameur, A., Jonson, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7125 · Cited by 74
Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy
Kornblau, S. M., Minden, M. D., Rosen, D. B., Putta, S., Cohen, A. C., Covey, T. M., Spellmeyer, D. C., Fantl, W. J., Gayko, U., & Cesano, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0093 · Cited by 62
A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue
Dairkee, S. H., Ji, Y., Ben, Y., Moore, D. H., Meng, Z., & Jeffrey, S. S. (2004) · BMC Genomics · doi:10.1186/1471-2164-5-47 · Cited by 61
Peptide Microarrays for Profiling of Serine/Threonine Kinase Activity of Recombinant Kinases and Lysates of Cells and Tissue Samples
Hilhorst, R., Houkes, L., Mommersteeg, M., Musch, J., van den Berg, A., & Ruijtenbeek, R. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-284-1_21 · Cited by 40
2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms
Nagourney, R., Evans, S., Messenger, J., Su, Y. Z., & Weisenthal, L. M. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.3 · Cited by 32
Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
Tahiri, A., Redalen, K. R., Ree, A. H., de Wijn, R., Risberg, K., Busch, C., Lønning, P. E., Kristensen, V. N., & Geisler, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072692 · Cited by 32
Overview of a chemoresponse assay in ovarian cancer
Grendys, E. C., Fiorica, J. V., Orr, J. W., Holloway, R. W., Wang, D., Tian, C., Chan, J. K., & Herzog, T. J. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1192-8 · Cited by 31
The Subrenal Capsule Assay in Selecting Chemotherapy for Ovarian Cancer: A Prospective Randomized Trial
Mäenpää, J., Heinonen, E. H., Hinkka‐Yli‐Salomäki, S., Karnani, P., Klemi, P. J., Korpijaakko, T. A., Kuoppala, T. A., Laine, A. M., Lähde, M., Nuoranne, E. K., et al. (1995) · Gynecologic Oncology · doi:10.1006/gyno.1995.1145 · Cited by 30
Direct Chemosensitivity Monitoring Ex Vivo on Undissociated Melanoma Tumor Tissue by Impedance Spectroscopy
Jahnke, H., Poenick, S., Maschke, J., Kendler, M., Simon, J. C., & Robitzki, A. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0813 · Cited by 27
A case study of personalized therapy for osteosarcoma
Davis, L. E., Hofmann, N. E., Li, G., Huang, E., Loriaux, M., Bracha, S., Helfand, S. C., Mata, J. E., Marley, K., Mansoor, A., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24512 · Cited by 25
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre‐B acute lymphoblastic leukemia
Glover, J., Loriaux, M., Tyner, J. W., Druker, B. J., & Chang, B. H. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23383 · Cited by 25
Sensor-based cell and tissue screening for personalized cancer chemotherapy
Kleinhans, R., Brischwein, M., Wang, P., Becker, B., Demmel, F., Schwarzenberger, T., Zottmann, M., Wolf, P. S., Niendorf, A., & Wolf, B. A. (2012) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-011-0855-7 · Cited by 24
Proteasome inhibitor carfilzomib complements ibrutinib’s action in chronic lymphocytic leukemia
Lamothe, B., Cervantes-Gomez, F., Sivina, M., Wierda, W. G., Keating, M. J., & Gandhi, V. V. (2015) · Blood · doi:10.1182/blood-2014-07-585364 · Cited by 24
Reliable and Effective Diagnostics Are Keys to Accelerating Personalized Cancer Medicine and Transforming Cancer Care: A Policy Statement from the American Association for Cancer Research
Sawyers, C. L., & Veer, L. V. ‘. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2295 · Cited by 21
Functional profiling to select chemotherapy in untreated, advanced or metastatic non-small cell lung cancer.
Nagourney, R. A., Blitzer, J. B., Shuman, R. L., Asciuto, T., Deo, E. A., Paulsen, M., Newcomb, R. L., & Evans, S. S. (2012) · PubMed · Cited by 17
Development and validation of a single‐cell network profiling assay‐based classifier to predict response to induction therapy in paediatric patients withde novoacute myeloid leukaemia: a report from the Children's Oncology Group
Lacayo, N. J., Alonzo, T. A., Gayko, U., Rosen, D. B., Westfall, M., Purvis, N. B., Putta, S., Louie, B., Hackett, J. R., Cohen, A. C., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12370 · Cited by 16
Dishing out cancer treatment
(2013) · Nature Biotechnology · doi:10.1038/nbt.2516 · Cited by 11
Functional Profiling of Live Melanoma Samples Using a Novel Automated Platform
Schayowitz, A., Bertenshaw, G. P., Jeffries, E., Schatz, T. F., Cotton, J. B., Villanueva, J., Herlyn, M., Krepler, C., Vultur, A., Xu, W., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052760 · Cited by 9
Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy.
Wheler, J. J., Yelensky, R., Stephen, B., Hong, D. S., Zinner, R., Subbiah, V., Fu, S., Karp, D. D., Falchook, G. S., Naing, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11019 · Cited by 9
Current Trends in Personalized Medicine and Companion Diagnostics: A Summary From the DIA Meeting on Personalized Medicine and Companion Diagnostics
Tsourounis, M., Stuart, J. N., Pignato, W., Toscani, M., & Barone, J. A. (2015) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479015570330 · Cited by 7
A molecular case report
Kulesz-Martin, M. F., Lagowski, J. P., Olson, S. B., Wortham, A. M., West, T. M., THOMAS, G. V., Ryan, C. W., & Tyner, J. W. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.22960 · Cited by 5

Sorted by citations

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., Falco, V. D., Upadhyay, A., Kandimalla, R. J. L., Chaudhary, A., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 2,011
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Self-citation
Organoids
Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,082
The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity
Xie, Y., Zhu, S., Song, X., Sun, X., Fan, Y., Liu, J., Zhong, M., Yuan, H., Zhang, L., Billiar, T. R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.055 · Cited by 952
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Sekhoacha, M. P., Riet, K., Motloung, P., Gumenku, L., Adegoke, A. M., & Mashele, S. S. (2022) · Molecules · doi:10.3390/molecules27175730 · Cited by 1,009

See all 571

Authors: Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T.
Affiliations: Harvard University (US)
Corresponding author: Friedman, Adam A.
ORCID: Friedman, Adam A.
Letai, Anthony
Fisher, David E.
Flaherty, Keith T.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2015-11-05
Volume: 15
Issue: 12
Pages: 747-756
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc4015
PMC: PMC4970460
OpenAlex: W2176372762
Cited by: 570
References: 108
Citations by year: 2026: 19 · 2025: 43 · 2024: 26 · 2023: 42 · 2022: 41 · 2021: 67 · 2020: 93 · 2019: 63 · 2018: 59 · 2017: 73 · 2016: 43
FWCI: 5.69
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (UM1CA186709, P01CA066996)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: precision oncology, functional diagnosis, chemosensitivity testing, genotype-phenotype correlation, next-generation sequencing, immune profiling, drug repurposing
MeSH terms: Humans, Neoplasms, Genomics, Molecular Diagnostic Techniques, Precision Medicine, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Precision medicine for cancer with next-generation functional diagnostics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks